Navigation Links
Independent Radiology Assessment Panel Results Confirm Statistical Significance of Response and Progression Endpoints of Cell Therapeutics' Pixantrone PIX301 Pivotal Trial
Date:9/27/2011

SEATTLE, Sept. 28, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) today announced that a second independent radiology assessment of response and progression endpoint data from CTI's PIX301 clinical trial of pixantrone confirmed the statistical robustness of the PIX301 efficacy data that was previously submitted by CTI to the U.S. Food and Drug Administration ("FDA") in CTI's new drug application ("NDA") for pixantrone.

This second independent assessment was recommended by the FDA's Office of New Drugs ("OND") as part of CTI's appeal of the Complete Response Letter ("CRL") for the NDA, which CTI received from the FDA's Office of Oncology Drug Products.

"The review conducted by a second independent panel of three radiologists confirmed the statistically and clinically significant results the first independent panel reported for the PIX301 study response and progression endpoints," noted James A. Bianco, M.D., CEO of CTI. "We now have two separate independent response assessment panels reporting significant results for complete response/complete response unconfirmed, overall response rate and progression-free survival at both end of treatment and end of study assessment periods as well as among the histologically confirmed aggressive non-Hodgkin's lymphoma ("NHL") subset of patients. We look forward to sharing these confirmatory results with the Division of Oncology Drug Products ("DODP") in our resubmission of the pixantrone NDA."

The review and the review process was conducted based on the recommendations by OND in order to determine that efficacy had been established by confirming confidence in the endpoint ascertainment and reliability of the primary results.

Based on the results of this second independent assessment panel's review, CTI plans on resubmitting the pixantrone NDA as early as October 2011 for accelerated approval.  The DODP previously confirmed that the review of the NDA would be complet
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Facet Solutions AFRS(TM) Demonstrates Biomechanical Advantages Over Dynamic Stabilization in Independent Testing
3. Independent Clinical Results Confirm Up to a 7-Centimeter Reduction in Body Circumference Using UltraShape(TM) Non-Invasive Fat Reduction and Body Contouring System
4. Independent Physician Surveys Show if Approved, MF101 Could Become First-Line Treatment for Menopause Symptoms
5. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R) Following Second Interim Review
6. Longevinex(R) Found to be Superior to Green Tea Molecule in Independent Human Study
7. Independent Studies Report on Possible Roles for Cylexs Immune Cell Function Assay in Monitoring of Heart and Lung Transplant Recipients
8. Seven Presentations by Two Independent Research Groups Highlight Advantages of Pressure Cycling Technology (PCT) at Scientific Symposia in Philadelphia, Boston, and New York City
9. Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer
10. Promise of Vicals CMV Vaccine Noted by Independent Experts
11. ASPIRE Independent Review Board Announces 10 Ways to Protect Participants Rights in Clinical Drug Trials and Optimize Results From Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Mass , Dec. 22, 2014 /PRNewswire/ -- RXi ... biotechnology company focused on discovering, developing and commercializing ... RNA-targeted technologies, today issued the following open letter ... Cauwenbergh , Dr. Med. Sc. Dear ... days a number of inaccurate statements posted on ...
(Date:12/22/2014)... -- TWi Biotechnology, Inc., today announced that it ... Biotechnology,s lead drug candidate, from The State Intellectual ... for patent application numbered 201180018154.8.  This patent includes ... for treatment of type II diabetes.  The patent ... for type II diabetes, and provides a protection ...
(Date:12/19/2014)... 2014  Advanced Medical Isotope Corporation ("AMIC") (OTCQB:  ... in the development of brachytherapy devices and medical ... that a Life Sciences Discovery Fund (LSDF) Proof ... AMIC is the commercialization partner.  The award was ... proposal titled "Optimized Injectable Radiogels for High-dose Therapy ...
Breaking Medicine Technology:RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 2TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 3Advanced Medical Isotope Corporation Awarded LSDF Grant As Commercialization Partner 2Advanced Medical Isotope Corporation Awarded LSDF Grant As Commercialization Partner 3
(Date:12/22/2014)... Pasadena sleep apnea dentist, ... apnea. Drowsy drivers are 15 times more likely to ... and some experts believe that sleep-deprived drivers may be ... Unfortunately, millions of Americans may be sleep-deprived without even ... Medicine, about 18 million Americans have sleep apnea, but ...
(Date:12/22/2014)... Luxury Linen purveyor Peacock Alley once again joined ... logistics and support for one of Dallas’ largest holiday toy ... of giving back to the community in which it lives ... were Whataburger® and 99.5 The Wolf. , There is no ... to children who would otherwise not receive any is a ...
(Date:12/22/2014)... Ill. (PRWEB) December 21, 2014 ... recommendations for chest computed tomography (CT) to evaluate ... relevant findings, including cancer, according to a new ... , Researchers said the findings show that radiologist ... represent valuable contributions to patient care. , RAIs, ...
(Date:12/21/2014)... (PRWEB) December 22, 2014 In ... is segmented by power source, product, and application. ... electric-powered, battery-powered, and pneumatic instruments. By product, the ... and accessories segments. The handpieces market is further ... devices, suction coagulators, laparoscopic instruments, shavers, wire/pin drivers, ...
(Date:12/21/2014)... Beverly Hills, Ca (PRWEB) December 21, 2014 ... Dr. Khanna was a guest at the Aspen Helicopters ... for kids and a Santa with sleigh, flown by ... the helicopter appeared invisible; only Santa with sleigh was ... both during day and night. Dr.Khanna has helped many ...
Breaking Medicine News(10 mins):Health News:Pasadena Dentist, Dr. Marine Martirosyan, Now Offers Consultations for Sleep Apnea 2Health News:Peacock Alley and Community Partners of Dallas Fulfill an Estimated 12,000 Holiday Wishes for Deserving Children 2Health News:RSNA: Radiologist Recommendations for Chest CT Have High Clinical Yield 2Health News:RSNA: Radiologist Recommendations for Chest CT Have High Clinical Yield 3Health News:Global Powered Surgical Instruments Market Hit to $2.1 billion by 2019 - New Research Report by MarketsandMarkets 2Health News:Global Powered Surgical Instruments Market Hit to $2.1 billion by 2019 - New Research Report by MarketsandMarkets 3Health News:Global Powered Surgical Instruments Market Hit to $2.1 billion by 2019 - New Research Report by MarketsandMarkets 4
... Faced with a barrage of pressing issues, the ... agenda. The timing bodes well for change, according ... University Center for Health Policy and Professionalism, associate professor ... a pediatrician at Riley Hospital for Children. , "If ...
... Feb. 6 Turner Construction Company, the nation,s leading ... Northern Inyo Hospital to proceed with the $42 million ... for Phase Two will start in March 2009 with ... of a new central plant, emergency rooms, ICU, CCU, ...
... Colo., Feb. 6 Baxa Corporation, an Englewood Colorado-based medical ... of the Top 50 Family-Owned Companies in Colorado. Qualifying ... be controlled by a single family, and controlling family members ... has to have been involved in the company for at ...
... Medical Group Inc.,(OTC Bulletin Board: WMDG; "Winner Medical"), ... and wound care products) in China, today,announced that ... first quarter,ended December 31, 2008 on Friday, February ... The earnings release will be available on the ...
... (Nasdaq: EVVV ) will release its 2008 fourth ... 2009 on Tuesday, Febuary 24, 2009, before regular market trading ... same day at 7:30 a.m. Central Time (8:30 a.m. Eastern ... full-year operating results and future outlook, followed by a question ...
... ... Brookfield, Wisconsin (PRWEB) February 6, 2009 -- Watching your weight? ... International Foundation of Employee Benefits Plans found that of those ... loss program., , ,When asked their primary reason for offering a ...
Cached Medicine News:Health News:Prioritizing health-care reform components 2Health News:Turner to Manage Construction of $42 Million Expansion of Northern Inyo Hospital in Bishop, Calif. 2Health News:Baxa Corporation Ranks Seventh in ColoradoBiz Magazine's Top 50 Family-Owned Companies 2Health News:Baxa Corporation Ranks Seventh in ColoradoBiz Magazine's Top 50 Family-Owned Companies 3Health News:Winner Medical Schedules 2008/2009 First Quarter Earnings Release on Friday, February 13, 2009 2Health News:ev3 Inc. to Report 2008 Fourth Quarter and Full-Year Financial Results and Host Conference Call on February 24, 2009 2Health News:Employee Weight Loss Programs Offered By Half of Employers Who Provide Wellness Programs 2Health News:Employee Weight Loss Programs Offered By Half of Employers Who Provide Wellness Programs 3
... The AFX Lens is ... for use in an air-filled ... use as a primary air-fluid ... profile and sutureless design make ...
... 45° Prism is designed ... and are recommended for ... BRVO etc.) and Rhegmatogenus ... be used for panretinal ...
... Chalam Flat is designed for ... and induction of posterior vitreous ... for macula whole surgery, epiretinal ... tractional epiretinal membranes. Direct image ...
... magnification and increased stereopsis, the Central Retinal ... to the equatorial regions. The Central Retinal ... in membrane peeling in proliferative vitreoretinopathy extending ... The ACS Vitrectomy Lenses from Volk can ...
Medicine Products: